Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;13(5):e2979.
doi: 10.1002/brb3.2979. Epub 2023 Mar 27.

Circulating lipocalin-2 as a novel biomarker for early neurological deterioration and unfavorable prognosis after acute ischemic stroke

Yi Xie  1 , Xingfeng Zhuo  2 , Kai Xing  1 , Zhenqian Huang  1 , Hongquan Guo  1 , Pengyu Gong  3 , Xiaohao Zhang  4 , Yun Li  1
Affiliations

Circulating lipocalin-2 as a novel biomarker for early neurological deterioration and unfavorable prognosis after acute ischemic stroke

Yi Xie et al. Brain Behav. 2023 May.

Abstract

Introduction: Lipocalin-2 (LCN2) is an acute-phase protein that could mediate neuroinflammation after brain injury. We aimed to evaluate if LCN2 level was associated with early neurological deterioration (END) in acute ischemic stroke patients, thus hindering clinical recovery.

Methods: We conducted a prospective study of acute ischemic stroke patients between June 2021 and February 2022. Serum LCN2 concentration was measured after admission using an enzyme-linked immunosorbent assay. Outcomes included END and 90-day poor functional outcome (modified Rankin Scale 3-6). The National Institutes of Health Stroke Scale increment ≥4 points within 72 h after admission was defined as END.

Results: A total of 253 acute ischemic stroke patients (mean age, 65.2 ± 13.4 years; 64.0% male) were recruited. In the multivariate adjustment, increased serum LCN2 levels (per 1-SD increase of LCN2) were associated with a higher risk of END (odds ratio [OR], 1.64; 95% confidence interval [CI], 1.20-2.25; p = .002) and 90-day poor outcome (OR, 1.73; 95% CI, 1.22-2.45; p = .002). Restricted cubic splines found a linear relationship between LCN2 level and 90-day unfavorable outcome (END, p = .001 for linearity; 90-day poor outcome, p = .013 for linearity). Subgroup analysis further confirmed the significant association of LCN2 with clinical outcomes.

Conclusions: This study demonstrated that higher circulating LCN2 level was associated with an increased risk of early clinical worsening and 90-day unfavorable outcomes in ischemic stroke patients.

Keywords: LCN2; biomarker; clinical worsening; functional outcome; ischemic stroke.

PubMed Disclaimer

Conflict of interest statement

All the authors declare that there is no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Subgroup analyses of the association between serum lipocalin‐2 (LCN2) and outcomes after ischemic stroke. Odds ratios (ORs) were calculated for each standard deviation (SD) increase in serum LCN2 levels after adjustment for age, sex, and variables with a p value <.1 in the univariate analysis, except for the stratified variable.
FIGURE 2
FIGURE 2
Association of serum lipocalin‐2 (LCN2) levels with risk of early neurological deterioration (END) (A) and 90‐day unfavorable outcome (B). Odds ratios and 95% confidence intervals were derived from restricted cubic spline regression, with knots placed at the 5th, 50th, and 95th percentiles of the distribution of LCN2. The reference point for serum LCN2 is the midpoint of the reference group from the categorical analysis. Odds ratios were adjusted for age, sex, and variables with a p value <.1 in the univariate analysis.
See this image and copyright information in PMC

References

    1. Adams, H. P. , Bendixen, B. H. , Kappelle, L. J. , Biller, J. , Love, B. B. , Gordon, D. L. , & Marsh, E. E. (1993). Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke; A Journal of Cerebral Circulation, 24(1), 35–41. 10.1161/01.STR.24.1.35 - DOI - PubMed
    1. Alawneh, J. A. , Moustafa, R. R. , & Baron, J.‐C. (2009). Hemodynamic factors and perfusion abnormalities in early neurological deterioration. Stroke; A Journal of Cerebral Circulation, 40(6), e443–e450. 10.1161/STROKEAHA.108.532465 - DOI - PubMed
    1. Al Nimer, F. , Elliott, C. , Bergman, J. , Khademi, M. , Dring, A. M. , Aeinehband, S. , Bergenheim, T. , Romme Christensen, J. , Sellebjerg, F. , Svenningsson, A. , Linington, C. , Olsson, T. , & Piehl, F. (2016). Lipocalin‐2 is increased in progressive multiple sclerosis and inhibits remyelination. Neurology Neuroimmunology & Neuroinflammation, 3(1), e191. 10.1212/NXI.0000000000000191 - DOI - PMC - PubMed
    1. Barber, P. , Demchuk, A. , Zhang, J. , & Buchan, A. (2000). Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet, 355(9216), 1670–1674. - PubMed
    1. Brott, T. , Adams, H. P. , Olinger, C. P. , Marler, J. R. , Barsan, W. G. , Biller, J. , Spilker, J. , Holleran, R. , Eberle, R. , & Hertzberg, V. (1989). Measurements of acute cerebral infarction: A clinical examination scale. Stroke; A Journal of Cerebral Circulation, 20(7), 864–870. 10.1161/01.STR.20.7.864 - DOI - PubMed

Publication types